Clinical Trial

Single-Arm Exploratory Study of PD-L1 Antibody Plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 9, 2025 (before its estimated August 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This single-arm exploratory study plans to enroll 69 locally advanced head and neck squamous cell carcinoma (LA-HNSCC) patients. Participants will receive Adebrelimab (PD-L1 antibody) plus TP regimen (docetaxel/cisplatin) as neoadjuvant therapy for 1-4 weeks, followed by surgery and subsequent follow-up phase.
Trial Details
NCT Number NCT07055841
Lead Sponsor Xiuping Ding
Conditions Squamous Cell Carcinoma of Head and Neck
Enrollment 69 participants
Start Date 2023-04-01
Primary Completion 2025-08-01 (estimated)
Study Completion 2026-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-09